News Evergreen Theragnostics 4/16/24 Evergreen Theragnostics 4/16/24 Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into Clinic, Prepare First Commercial Launch, and Expand Industry-Leading CDMO Services Read More Evergreen Theragnostics 9/25/23 Evergreen Theragnostics 9/25/23 UPPI and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More Evergreen Theragnostics 6/23/23 Evergreen Theragnostics 6/23/23 Jubilant Radiopharma and Evergreen Theragnostics Launch Collaboration for the Sale and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More Evergreen Theragnostics 6/13/23 Evergreen Theragnostics 6/13/23 PharmaLogic and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More Evergreen Theragnostics 6/8/23 Evergreen Theragnostics 6/8/23 CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US Read More Evergreen Theragnostics 5/18/23 Evergreen Theragnostics 5/18/23 RLS and Evergreen Theragnostics launch partnership for sale and distribution of neuroendocrine tumor diagnostic Octevy™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval Read More Evergreen Theragnostics 4/3/23 Evergreen Theragnostics 4/3/23 Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals Read More Evergreen Theragnostics 3/27/23 Evergreen Theragnostics 3/27/23 Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit, and Prepares Ga-68 DOTATOC Supply Chain Read More Evergreen Theragnostics 12/12/22 Evergreen Theragnostics 12/12/22 Evergreen Theragnostics Submits New Drug Application for Gallium-68 DOTATOC Kit with US FDA Read More Evergreen Theragnostics 8/18/22 Evergreen Theragnostics 8/18/22 Clarity and Evergreen expand Targeted Copper Theranostics manufacturing Read More Evergreen Theragnostics 3/16/22 Evergreen Theragnostics 3/16/22 Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 Read More Evergreen Theragnostics 12/1/21 Evergreen Theragnostics 12/1/21 MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals Read More Evergreen Theragnostics 10/18/21 Evergreen Theragnostics 10/18/21 Evergreen Theragnostics Completes New Jersey Manufacturing Facility Read More Evergreen Theragnostics 9/30/21 Evergreen Theragnostics 9/30/21 Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials Read More Evergreen Theragnostics 8/16/21 Evergreen Theragnostics 8/16/21 Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Read More Evergreen Theragnostics 7/14/21 Evergreen Theragnostics 7/14/21 Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities Read More Evergreen Theragnostics 4/28/21 Evergreen Theragnostics 4/28/21 Precirix partners with Evergreen to expand North American clinical trial supply Read More Evergreen Theragnostics 9/23/20 Evergreen Theragnostics 9/23/20 Evergreen Theragnostics Begins Construction of New Manufacturing Facility Read More Evergreen Theragnostics 6/22/20 Evergreen Theragnostics 6/22/20 Evergreen Theragnostics Completes $19 Million Series A Capital Raise Read More
Evergreen Theragnostics 4/16/24 Evergreen Theragnostics 4/16/24 Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into Clinic, Prepare First Commercial Launch, and Expand Industry-Leading CDMO Services Read More
Evergreen Theragnostics 9/25/23 Evergreen Theragnostics 9/25/23 UPPI and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More
Evergreen Theragnostics 6/23/23 Evergreen Theragnostics 6/23/23 Jubilant Radiopharma and Evergreen Theragnostics Launch Collaboration for the Sale and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More
Evergreen Theragnostics 6/13/23 Evergreen Theragnostics 6/13/23 PharmaLogic and Evergreen Theragnostics Announce Partnership for Sales and Distribution of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023 Read More
Evergreen Theragnostics 6/8/23 Evergreen Theragnostics 6/8/23 CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US Read More
Evergreen Theragnostics 5/18/23 Evergreen Theragnostics 5/18/23 RLS and Evergreen Theragnostics launch partnership for sale and distribution of neuroendocrine tumor diagnostic Octevy™ (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval Read More
Evergreen Theragnostics 4/3/23 Evergreen Theragnostics 4/3/23 Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals Read More
Evergreen Theragnostics 3/27/23 Evergreen Theragnostics 3/27/23 Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit, and Prepares Ga-68 DOTATOC Supply Chain Read More
Evergreen Theragnostics 12/12/22 Evergreen Theragnostics 12/12/22 Evergreen Theragnostics Submits New Drug Application for Gallium-68 DOTATOC Kit with US FDA Read More
Evergreen Theragnostics 8/18/22 Evergreen Theragnostics 8/18/22 Clarity and Evergreen expand Targeted Copper Theranostics manufacturing Read More
Evergreen Theragnostics 3/16/22 Evergreen Theragnostics 3/16/22 Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 Read More
Evergreen Theragnostics 12/1/21 Evergreen Theragnostics 12/1/21 MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals Read More
Evergreen Theragnostics 10/18/21 Evergreen Theragnostics 10/18/21 Evergreen Theragnostics Completes New Jersey Manufacturing Facility Read More
Evergreen Theragnostics 9/30/21 Evergreen Theragnostics 9/30/21 Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials Read More
Evergreen Theragnostics 8/16/21 Evergreen Theragnostics 8/16/21 Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Read More
Evergreen Theragnostics 7/14/21 Evergreen Theragnostics 7/14/21 Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities Read More
Evergreen Theragnostics 4/28/21 Evergreen Theragnostics 4/28/21 Precirix partners with Evergreen to expand North American clinical trial supply Read More
Evergreen Theragnostics 9/23/20 Evergreen Theragnostics 9/23/20 Evergreen Theragnostics Begins Construction of New Manufacturing Facility Read More
Evergreen Theragnostics 6/22/20 Evergreen Theragnostics 6/22/20 Evergreen Theragnostics Completes $19 Million Series A Capital Raise Read More